Indoco Remedies Gears Up for Q3 Reveal on 3rd February; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Indoco Remedies’s Q3 results FY26 are scheduled to be announced on 3rd February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Indoco Remedies Q3 Results 2026 Preview

• Indoco Remedies’ revenue is expected to be in the range of ₹410.55 crore, a 5.11% YoY decrease. 
• Profit After Tax, or PAT, is projected to rise by 175.76% YoY. 
• Net profit is ₹26.29 crore, up 175.76% YoY 
• EBITDA to rise 0.00%

Indoco Remedies Share Performance 

• Over the past six months, Indoco Remedies’s share price has fallen by 10.40% to ₹922.00.
• Moreover, over the past year, the stock has decreased by 89.03%.
• Despite this weak short-term performance, Indoco Remedies’s stock has delivered a financially sound 681.69% return over the past 5 years.
• As of 3rd February 2026, the stock traded at ₹922.00 per share.

Key Factors to Watch for Indoco Remedies Q3 Results FY26 

• Revenue & Volume Growth: Look at topline performance — growth in domestic sales and export markets (especially regulated markets like the US) to gauge demand momentum.
  
• Profitability & Margins: EBITDA and net profit margins will show how well the company is managing costs, pricing pressures, and product mix.
  
• US & Regulated Market Performance: Performance in the US and other regulated markets is important since these are higher-margin geographies and can significantly impact earnings.
  
• New Product Approvals & Launches: Updates on ANDA approvals, product launches, and commercialization timelines — new products can drive future revenue growth.
  
• Cost & Input Trends: Raw material costs, forex impact, and operating expenses — especially if API/finished dosage costs fluctuate — affecting profitability and cash flow.

Final Thoughts

Indoco Remedies will announce its Q3 FY26 results on 2nd February 2026. Analysts expect 9.% YoY1.02% revenue growth, a 4.46% fall in PAT, and a 9.17% fall in EBITDA. Indoco Remedies focuses on formulation manufacturing for domestic and export markets, with emphasis on regulated market presence, new product launches, cost control, and margin improvement.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here